Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.4.99.7 (sialyltransferase)
 1,534 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Highly purified fractions of gamma-glutamyl transpeptidase [gamma-glutamyltrinsferase; (5-glutamyl)-peptide:amino-acid 5-glutamyltransferase, EC 2.3.2.2] from normal and malignant rat mammary tissue were prepared. Analyses by isoelectric focusing indicate the existence of at least 12 enzymatically active species. The gamma-glutamyl transpeptidase from the tumor tissue had a greater proportion of the activity concentrated in the more negative species than the enzyme from normal tissue. Treatment of the two enzyme preparations with neuraminidase (acylneuraminyl hydrolase, EC 3.2.1.18) greatly reduced this difference. When whole tissue homogenates were treated with papain to solubilize the enzyme and then focused, the same relationship held. The neuraminidase activities in the two homogenates were similar, but the sialytransferase activity (CMP-N-acetylneuraminate:D-galactosyl-glycoprotein N-acetylneuraminyltransferase, EC 2.4.99.1) of the tumor homogenate was 13 times that of the normal mammary homogenate. These observations suggest that the gamma-glutamyl transpeptidase of the tumor is more heavily sialylated than that from the normal tissue, possibly reflecting the greater sialyltransferase activity of the tumor.
 ...
PMID:Differences in the isoelectric focusing patterns of gamma-glutamyl transpeptidase from normal and cancerous rat mammary tissue. 2 38

A serum B12-binding protein with increased sialic acid content (termed hepatoma B12-binding protein) that causes elevations of serum B12 and unsaturated B12-binding capacity has been found in some patients with hepatocellular carcinoma (hepatoma). We now report another patient with hepatoma with initial near-normal, unsaturated B12-binding capacity that increased 400-fold as the disease progressed and then fell 50% with response to chemotherapy. A perfusate of the tumor in the liver had 5 times more B12-binding protein than did the serum and was immunologically the same as the serum hepatoma B12-binding protein isolated from previous cases. A cell line derived from hepatoma produced significant amounts of B12-binding protein similar to hepatoma B12-binding protein, whereas cell lines from normal liver and other neoplasia did not. The hepatoma sera, perfusate, and media from the hepatoma cell line contained elevated sialyltransferase activity. These data suggest that some hepatomas produce increased hypersialylated B12-binding protein that is cleared slowly from the plasma and accumulates there as hepatoma B12-binding protein.
 ...
PMID:The clinical and physiological implications of hepatoma B12-binding proteins. 6 88

When compared to uninvolved adjacent tissue, metastatic tumors in human liver appear to have significantly reduced sialytransferase activity. No significant kinetic differences (Michaelis constants, thermostability, and pH optima) between noncancerous and cancerous tissue sialytransferase were found. Mixing experiments between cancerous and noncancerous tissues indicated that inhibitors of sialytransferase activity were present in cancerous tissue. Subsequent experiments demonstrated increased levels of bound sialic acid in the tumor tissues. Inasmuch as futuin, a sialoglycoprotein, inhibits sialyltransferase activity, the increased levels of bound sialic acid in tumor tissue may be responsible for the reduced enzyme activity in these tissues.
 ...
PMID:Characterization of sialytransferase in noncancerous and neoplastic human liver tissue. 8 33

The following three parameters were studied in Morris hepatomas of different growth rates: (a) the specific activity of guanosine dephosphate (GDP)-fucose:glycoprotein fucosyltransferase and cytidine monophosphate (CMP)-N-acetylneuraminic acid:glycoprotein sialyltransferase, (B) the content of GDP-fucosee and CMP-N-acetylneuraminic acid, and (c) the activity of alpha-L-fucosidase and neuraminidase. Fucosyltrasferase activities were significantly elevated in all hepatomas investigated. Especially high levels of enzyme were measured in the rapidly growing tumors 7777, 66, and 3924A. The increase varied between 2- and 3-fold when compared with the corresponding host liver. Conversely, the activity of the sialytransferase was greatly decreased in all hepatoma lines with a rapid or intermediate growth rate. In the fast-growing tumor 9618A2, the activity was reduced to 8%. GDP-fucose and CMP-N-acetylneuraminic acid were determined by the isotope dilution technique. In normal rat liver from Buffalo or ACl rats, the concentration of GDP-fucose was 6.5+/-0.9 and 9.5+/-1.1nmoles/g, wet weight, respectively. In the fast-growing hepatomas 3924A and 9121, levels up to 21.5 nmoles/g, wet weight, were found, However, the content of CMP-N-acetylneuraminic acid in hepatomas was indluenced to a lesser extent by the degree of differentiation of the tumor. In the most rapidly growing tumor, 9618A2, a level of alpha-L- fucosidase seven times higher than in host liver was determined. Moreover, there existed a correlation bewteen the age of the hepatoma and enzyme activity. Within the 2nd week after inoculation, fucosidase activity increased from 130 to 343 nmoles/hr/mg of protein. Neuraminidase was measured in a new linked assay system. The activity of this enzyme was lowered by 50% or was at least unchanged when compared to the activity in host liver. Our results indicate that specific alterations of fucose metabolism are a characteristic feature of Morris hepatomas.
 ...
PMID:Glycosyltransferases and glycosidases in Morris hepatomas. 19 53

Serum levels of sialyltransferase and sialic acid were measured in patients with malignant melanomas (n = 49), healthy control persons (n = 20), and patients with non-malignant skin disorders (n = 30). Both parameters were found to be higher in malignant melanoma patients than in healthy control persons, but they were not significantly higher in melanoma patients than in patients with benign skin disorders, unless widespread dissemination of metastases had occurred. The highest values were measured in patients with liver and lung metastases. No general correlation was found between sialyltransferase activities and sialic acid concentrations. Sialic acid concentrations seem to be a better index for tumor spreading than sialyltransferase activities. In early stages of the disease, shedding from tumor cells is not the major source of elevated serum levels of sialyltransferase and sialic acid, respectively.
 ...
PMID:Sialyltransferase levels and sialic acid concentrations in sera of patients with malignant melanomas. 47 55

Rats with transplantable spontaneously metastasizing mammary tumors have elevated levels of both serum sialoglycoconjugate and serum sialytransferase activity compared with normal female rats or rats with various nonmetastasizing mammary tumors. A direct relationship was observed between the amount of serum protein-bound sialic acid and serum sialyltransferase activity in all rats studied. Serum sialyltransferase activity in rats with a representative metastasizing mammary tumor, SMT-2A, was also correlated with tumor age. Microsomes prepared from the SMT-2A tumor have a sixfold higher sialyltransferase activity than do microsomes prepared from the nonmetastasizing mammary tumor MT-W9B. Normal rat liver microsomes have the same level of activity as microsomes prepared from livers of animals with either SMT-2A or MT-W9B tumors. The data indicate that spontaneously metastasizing mammary tumor cells have an increased production and release, perhaps through cell surface shedding, of a sialyltransferase. It is suggested that this sialyltransferase may increase the serum half-life of certain tumor-specific circulating glycoconjugates by increasing the content of protein-bound sialic acid and may thereby play a role in the immune escape mechanism of metastasizing tumor cells.
 ...
PMID:Concomitant elevations in serum sialytransferase activity and sialic acid content in rats with metastasizing mammary tumors. 83 14

Elevated levels of three plasma glycosyltransferases were associated with neoplasia in cancer patients, notably those with tumor metastatic to liver. We examined levels of sialyltransferase, galactosyltransferase, and fucosyltransferase in metastatic tumor and apparently uninvolved host liver tissue in attempts to delineate possible sources of elevated plasma enzyme levels. Highest levels of fucosyltransferase activity were found associated with tumor tissue; in contrast, sialyltransferase and galactosyltransferase activity was often highest at the tumor-liver interface.
 ...
PMID:Glycosyltransferase levels in tumors metastatic to liver and in uninvolved liver tissue. 87 59

Levels of glycoprotein:sialyltransferase activity (EC 2.4.99.1; CMP-acetyl-neuraminate:D-galactosyl-glycoprotein N-acetylneuraminyl-transferase) were measured in plasma of patients with neoplastic disease, and were found elevated above normal control values in 85% of patients examined. There was a correlation between enzyme levels and course of disea-e in 46 of 57 patients studied serially during therapy. Plasma sialyltransferase may be a useful marker enzyme for monitoring effectiveness of therapeutic programs for disseminated neoplasms.
 ...
PMID:Alterations in plasma sialyltransferase levels in patients with neoplastic disease. 91 50

Levels of plasma sialyltransferase were measured in a patient with disseminated carcinoma of the testes. Initial enzyme values, elevated six fold above those in normal controls, were among the highest thus far encountered in a population of patients with various stages and types of malignancy. During a remarkable respose to chemotherapy with cis-diaminodichloroplatinum, plasma sialyltransferase levels fell markedly. Serial measurement of this enzyme may aid in evaluation of tumor responsiveness to therapy in patients whose disease is not readily measurable.
 ...
PMID:Alterations in plasma sialyltransferase associated with successful chemotherapy of a disseminated tumor. Case report. 99 Nov 25

Glycosyltransferase enzymes were measured in homogenates of normal and neoplastic colon epithelium. The levels for exogenous galactosyltransferase and fucosyltransferase and endogenous N-acetylglucosaminyl-transferase were higher in the normal tissue. The levels for exogenous and endogenous sialyltransferase and endogenous galactosyltransferase and fucosyltransferase were comparable in the homogenates of normal and cancer cells. Incorporation of fucose and galactose into purified carcinoembryonic antigen (CEA), used as an exogenous acceptor by colon glycosyltransferases, was demonstrated by immunoprecipitation with rabbit antiserum to human CEA. The normal fucosyltransferase and galactosyltransferase showed higher activity with CEA than did the tumor enzymes.
 ...
PMID:Alterations in glycosyltransferase activity in human colon cancer. 111 12


1 2 3 4 5 6 7 8 9 10 Next >>